Kitov’s NT-219, is a first-in-class, novel small molecule designed to overcome cancer drug resistance. NT-219 is currently in pre-clinical development. NT-219 targets IRS1/2 and STAT3 – two signal proteins that are part of an anti-cancer drug resistance mechanism. In preclinical models where NT-219 was administered in combination with various oncology therapies, it demonstrated outstanding efﬁcacy in preventing acquired resistance and reversing tumor resistance was demonstrated. These therapies include EGFR Antibodies (Erbitux®), small molecular inhibitors of MEK (Mekinist®), mutated BRAF (Zelboraf®), EGFR (Tagrisso®, Tarceva®), and mTOR (Afinitor®), as well as with chemotherapy agents such as Gemcitabine, Oxaliplatin, and Docetaxel. Preliminary synergistic effects were also observed in combination with immune oncology agents such as Keytruda®.